Evidence map›Paper›PMID 35047452›Full record

ArticleJournal of cancer prevention2021

Evaluation of the Value of Multiplex MicroRNA Analysis as a Breast Cancer Screening in Korean Women under 50 Years of Age with a High Proportion of Dense Breasts.

Ji Young Jang, Eun Young Ko, Ji Soo Jung, Kyung Nam Kang, Yeon Soo Kim, Chul Woo Kim

Abstract read
In one paragraph

Article in Journal of cancer prevention, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ji Young Jang *BIOINFRA Life Science Inc., Seoul, Korea.ORCID https://orcid.org/0000-0003-4347-9245
Eun Young Ko *BIOINFRA Life Science Inc., Seoul, Korea.ORCID https://orcid.org/0000-0001-9406-4395
Ji Soo JungBIOINFRA Life Science Inc., Seoul, Korea.ORCID https://orcid.org/0000-0001-7230-9099
Kyung Nam KangBIOINFRA Life Science Inc., Seoul, Korea.ORCID https://orcid.org/0000-0002-2976-3920
Yeon Soo KimDIOGENE Inc., Seongnam, Korea.ORCID https://orcid.org/0000-0002-6516-7085
Chul Woo KimBIOINFRA Life Science Inc., Seoul, Korea.ORCID https://orcid.org/0000-0002-1229-198X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was conducted to confirm the performance of the microRNA (miRNA) biomarker combination as a new breast cancer screening method in Korean women under the age of 50 with a high percentage of dense breasts. To determine the classification performance of a set of miRNA biomarkers (miR-1246, 202, 21, and 219B) useful for breast cancer screening, we determined whether there was a significant difference between the breast cancer and healthy control groups through box plots and the Mann-Whitney U-test, which was further examined in detail by age group. To verify the classification performance of the 4 miRNA biomarker set, 4 classification methods (logistic regression, random forest, XGBoost, and generalized linear model plus random forest) were applied, and 10-fold cross-validation was used as a validation method to improve performance stability. We confirmed that the best breast cancer detection performance was achievable in patients under 50 years of age when the set of 4 miRNAs were used. Under the age of 50, the 4 miRNA biomarkers showed the highest performance with a sensitivity of 85.29%, specificity of 93.33%, and area under the curve (AUC) of 0.961. Examining the results of 4 miRNA biomarkers was found to be an effective strategy for diagnosing breast cancer in Korean women under 50 years of age with dense breasts, and hence has the potential as a new breast cancer screening tool. Further validation in an appropriate screening population with large-scale clinical trials is required.

Indexed as

Breast cancerDense breastKorean women under the age of 50MicroRNAScreening

Identifiers

PMID35047452
PMCPMC8749312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.